Relationship between cytokeratin staining patterns and clinico-pathological features in somatotropinomae

被引:81
作者
Bakhtiar, Yuriz [1 ]
Hirano, Hirofumi [1 ]
Arita, Kazunori [1 ]
Yunoue, Shunji [1 ]
Fujio, Shingo [1 ]
Tominaga, Atsushi [2 ]
Sakoguchi, Tetsuhiko [2 ]
Sugiyama, Kazuhiko [2 ]
Kurisu, Kaoru [2 ]
Yasufuku-Takano, Junko [3 ]
Takano, Koji [3 ]
机构
[1] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Neurosurg, Kagoshima 8908520, Japan
[2] Hiroshima Univ, Grad Sch Biomed Sci, Dept Neurosurg, Hiroshima 7348551, Japan
[3] Univ Tokyo, Fac Med, Dept Nephrol & Endocrinol, Tokyo 1138655, Japan
关键词
THYROTROPIN-RELEASING-HORMONE; SECRETING PITUITARY-ADENOMAS; FIBROUS BODIES; CLINICAL CHARACTERISTICS; ACROMEGALIC PATIENTS; E-CADHERIN; EXPRESSION; GS; MUTATIONS; TUMORS;
D O I
10.1530/EJE-10-0586
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Somatotropinomae are classified as densely and sparsely granulated adenomae, which typically exhibit a perinuclear pattern (PP) and a dot pattern (DP) in cytokeratin (CK) immunostaining respectively. Some exhibit a mixed pattern (MP). We studied the relationship between these somatotropinoma subtypes and their clinico-pathological features. Methods: The study population consisted of 141 Japanese acromegalic patients. We evaluated their clinical presentation and their response to provocation tests with TRH and LHRH and to suppression (octreotide) test. Tumour tissues were subjected to immunostaining for CAM-5.2, MIB-1, CD34, E-cadherin (CDH1) and p53 (TP53). In 43 cases (30 non-DP and 13 DP), we analysed gsp mutations (constitutively activating mutations of the G(s)alpha protein that is encoded by GNAS gene). Results: The 141 adenomae were categorised into three subtypes based on their CK staining patterns; 30 (21.3%) exhibited DP, 83 (58.9%) exhibited PP, and 28 (19.9%) exhibited MP. Compared with the other subtypes, DP adenomae were significantly larger, and their E-cadherin expression and response to TRH, LHRH and octreotide challenge were lower. The postoperative cure rate tended to be lower in DP adenomae. gsp mutations were detected in 25 of 43 cases examined (58.1%); 20 of the 30 non-DP (66.7%) and 5 of the 13 DP tumours (38.5%) were affected by the mutation. Conclusion: DP somatotropinomae exhibit characteristic features. Compared with the non-DP subtypes, DP adenomae manifested a larger tumour size, a lower incidence of abnormal responses to TRH and LHRH challenge, a poor response to octreotide test and a lower expression of E-cadherin. gsp mutation was not exclusive for non-DP somatotropinomae.
引用
收藏
页码:531 / 539
页数:9
相关论文
共 47 条
[1]   CLINICAL AND BIOCHEMICAL CHARACTERISTICS OF ACROMEGALIC PATIENTS HARBORING GSP-POSITIVE AND GSP-NEGATIVE PITUITARY-TUMORS [J].
ADAMS, EF ;
BROCKMEIER, S ;
JAMES, CD ;
FRIEDMANN, E ;
ROTH, M ;
TINDALL, GT ;
BUCHFELDER, M ;
FAHLBUSCH, R ;
POST, KD ;
MORGELLO, S .
NEUROSURGERY, 1993, 33 (02) :198-203
[2]   Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome [J].
Akintoye, SO ;
Chebli, C ;
Booher, S ;
Feuillan, P ;
Kushner, H ;
Leroith, D ;
Cherman, N ;
Bianco, P ;
Wientroub, S ;
Robey, PG ;
Collins, MT .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (11) :5104-5112
[3]   DELAYED ASSEMBLY OF DESMOSOMES IN KERATINOCYTES WITH DISRUPTED CLASSIC-CADHERIN-MEDIATED CELL-ADHESION BY A DOMINANT-NEGATIVE MUTANT [J].
AMAGAI, M ;
FUJIMORI, T ;
MASUNAGA, T ;
SHIMIZU, H ;
NISHIKAWA, T ;
SHIMIZU, N ;
TAKEICHI, M ;
HASHIMOTO, T .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1995, 104 (01) :27-32
[4]  
ASA SL, 1998, ATLAS TUMOR PATHOL, P47
[5]   A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors [J].
Asa, Sylvia L. ;
DiGiovanni, Rebecca ;
Jiang, Jing ;
Ward, Megan L. ;
Loesch, Kimberly ;
Yamada, Shozo ;
Sano, Toshiaki ;
Yoshimoto, Katsuhiko ;
Frank, Stuart J. ;
Ezzat, Shereen .
CANCER RESEARCH, 2007, 67 (15) :7505-7511
[6]   The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly [J].
Bhayana, S ;
Booth, GL ;
Asa, SL ;
Kovacs, K ;
Ezzat, S .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (11) :6290-6295
[7]   Postoperative persistent thyrotrophin releasing hormone-induced growth hormone release predicts recurrence in patients with acromegaly [J].
Biermasz, NR ;
Smit, JWA ;
van Dulken, H ;
Roelfsema, F .
CLINICAL ENDOCRINOLOGY, 2002, 56 (03) :313-319
[8]   Clinical Correlates in Acromegalic Patients with Pituitary Tumours Expressing GSP Oncogenes [J].
M. Buchfelder ;
R. Fahlbusch ;
T. Merz ;
H. Symowski ;
E.F. Adams .
Pituitary, 1999, 1 (3-4) :181-185
[9]   Keratin expression in human tissues and neoplasms [J].
Chu, PG ;
Weiss, LM .
HISTOPATHOLOGY, 2002, 40 (05) :403-439
[10]   In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide [J].
Ezzat, S ;
Kontogeorgos, G ;
Redelmeier, DA ;
Horvath, E ;
Harris, AG ;
Kovacs, K .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1995, 133 (06) :686-690